In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Feature|Articles|August 13, 2025
- Vol 53 No 08
- Volume 53
- Issue 08
What should the adult urologist know about pediatric urologic cancers?
Author(s)Jonathan Walker, MD, Amanda Buchanan, MD
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
"Pediatric-type cancer diagnoses in adults are rare, and there are important differences in caring for children with genitourinary malignancies compared with adults," write the authors.
Advertisement
Advertisement
Fortunately for patients and families, pediatric urologic oncology is a relatively small component of both pediatric urology and pediatric oncology practice. Despite the rarity of these diagnoses, there is an important role that both the pediatric and adult urologist can play in the management of kidney,
Related to this article
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
The PDUFA target action date is in the fourth quarter of 2026.
Advertisement
Advertisement